MARKET

HNSBF

HNSBF

Hansa Medical AB
EXMKT
2.900
NaN%
Closed 09:30 04/02 EDT
OPEN
--
PREV CLOSE
2.900
HIGH
--
LOW
--
VOLUME
--
TURNOVER
--
52 WEEK HIGH
3.300
52 WEEK LOW
2.900
MARKET CAP
295.11M
P/E (TTM)
-4.0673
1D
5D
1M
3M
1Y
5Y
1D
Hansa Biopharma Raises USD 30 Million via Convertible Notes to Back U.S. Imlifidase Launch
TipRanks · 03/20 07:36
Hansa Biopharma to Present Commercial Strategy at Redeye Life Science Event
TipRanks · 03/13 11:32
Hansa Biopharma to Spotlight Immunomodulatory Platform at DNB Carnegie Healthcare Conference
TipRanks · 03/10 09:33
Hansa Biopharma leadership to spotlight growth strategy at LSX Investival USA
TipRanks · 03/09 09:02
Hansa Biopharma to Spotlight Immunomodulatory Platform at Leerink Global Healthcare Conference
TipRanks · 03/06 17:03
Imlifidase: Extended FDA Review Seen as Timing-Driven, Not Risk-Driven, Supporting Buy Rating on Strong Unmet-Need and Efficacy Profile
TipRanks · 03/05 18:15
Hansa Biopharma Secures FDA PDUFA Date for Imlifidase in High-Risk Kidney Transplant Patients
TipRanks · 03/04 22:03
Hansa Biopharma to Present Corporate Strategy at TD Cowen Health Care Conference
TipRanks · 02/23 16:33
More
About HNSBF
Hansa Biopharma AB, formerly Hansa Medical AB, is a Sweden-based biopharmaceutical company with focus on immunomodulatory enzymes for treatment and prevention of rare and severe autoimmune conditions and transplant rejection. The Company’s operations consist of research and development for drug discovery. The Company conducts several projects, among which primary are IdeS (Immunoglobulin G-degrading enzyme of Streptococcus pyogenes) and HBP-assay (Heparin Binding Protein-assay). IdeS’s goal is to enable transplantation that prevents antibody-mediated rejection. HBP-assay is a diagnostic method that aims to predict severe sepsis in patients with infectious disease symptoms. The Company’s patent portfolio consists of several patent families that geographically cover numerous jurisdictions, including the United States, Europe and Japan.

Webull offers Hansa Biopharma AB stock information, including EXMKT: HNSBF real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, HNSBF stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading HNSBF stock methods without spending real money on the virtual paper trading platform.